21:20 , Apr 28, 2017 |  BioCentury  |  Finance

A different animal?

For the second time, macro factors will make it hard to divine how much impact, if any, a clinical failure at Circassia Pharmaceuticals plc will have on investor sentiment in the U.K. But at least...
20:35 , Apr 18, 2017 |  BC Extra  |  Clinical News

Circassia abandoning allergy field after Phase IIb miss

Circassia Pharmaceuticals plc (LSE:CIR) said it will no longer develop allergy therapeutics following the failure of dust mite program HDM-SPIRE in a Phase IIb trial. The company plans to focus on its respiratory business, including...
07:00 , Jun 27, 2016 |  BioCentury  |  Finance

Nine lives?

Whether Circassia Pharmaceuticals plc's implosion will have a lasting effect on the U.K. biotech sector is going to be hard to tease out now that the Brexit has thrown London and the global markets into...
00:38 , Jun 21, 2016 |  BC Extra  |  Top Story

Circassia plummets after Phase III cat allergy failure

Circassia Pharmaceuticals plc (LSE:CIR) fell 179.30p (66%) to 91p and shed L510.8 million in market cap Monday after its Cat-SPIRE missed the primary endpoint in the Phase III CATALYST study to treat moderate to severe...
01:31 , Mar 30, 2016 |  BC Extra  |  Company News

Management tracks

Gilead Sciences Inc. (NASDAQ:GILD) SVP of Hematology and Oncology Therapeutics Philippe Bishop has left the company. Oncology company Medivation Inc. (NASDAQ:MDVN) named Jennifer Jarrett CFO, effective April 23. She will replace Rick Bierly, who will...
07:00 , Jul 13, 2015 |  BioCentury  |  Finance

Mid-cap hot streak

Almost all of the biotech market cap tiers tracked by BioCentury ended the second quarter in the black. The lone exception was companies valued below $200 million, which collectively fell a median 1.2%. Big...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Company News

Aerocrine, Circassia deal

Circassia completed its acquisition of Aerocrine for SEK2.55 per share (see BioCentury, June 15). Aerocrine AB, Solna, Sweden   Circassia Pharmaceuticals plc (LSE:CIR), Oxford, U.K.   Business: Inflammation   ...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Financial News

Circassia completes placing and open offer

Circassia Pharmaceuticals plc (LSE:CIR), Oxford, U.K.   Business: Inflammation   Date completed: 2015-06-09   Type: Placing and open offer   Raised: L275 million ($420.1 million)   Shares: 95.5 million   Price: 288.05p   Shares after offering: 284.9 million   Investors: JPMorgan; Peel Hunt...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Company News

Aerocrine, Circassia deal

Circassia will acquire Aerocrine for SEK2.55 per share, or about SEK1.8 billion ($215.1 million) in cash. The price is an 18% premium to Aerocrine’s close of SEK2.17 on May 14, the day before the deal...
01:51 , Jun 10, 2015 |  BC Extra  |  Financial News

Circassia raises L275M to fund pair of acquisitions

Allergy company Circassia Pharmaceuticals plc (LSE:CIR) raised L275 million ($420.1 million) through the sale of 95.5 million shares at L2.88 in a placing and open offer underwritten by JPMorgan Cazenove and Peel Hunt. The sale...